Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VAOII
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-EGFR-Sulfo-SMCC-DM1
|
|||||
| Synonyms |
Anti-EGFR Sulfo-SMCC DM1
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-EGFR mAb
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Sulfo-SMCC
|
Linker Info | ||||
| Conjugate Type |
The SulfoSMCC linker reacted with the 10 lysine residues of antiEGFR mAb, forming a stable amide bond.
|
|||||
| Combination Type |
Sulfo-SMCC-DM1
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.